Screener
ImmunityBio, Inc. IBRX Total Assets
Total Assets at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:Assets.
The source filing: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:37 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001326110-26-000059
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease right-of-use assets, net – related parties | 12,461 | 13,202 |
| Other assets | 15,746 | 4,530 |
| Other assets – related parties | 378 | 378 |
| Total assets | $646,637 | $501,898 |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||
| Current liabilities: | ||
| Accounts payable | $11,192 | $6,978 |
| Accrued expenses and other liabilities | 48,204 | 46,838 |
ITEM 1. FINANCIAL STATEMENTS.
FAQ
- What is ImmunityBio, Inc.'s total assets?
- ImmunityBio, Inc. (IBRX) reported total assets of $646.64M in Q1 2026.
- How has ImmunityBio, Inc.'s total assets changed year-over-year?
- ImmunityBio, Inc.'s total assets increased by 112.9% year-over-year, from $303.76M to $646.64M.
- What is the long-term trend for ImmunityBio, Inc.'s total assets?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s total assets has grown at a 17.8% compound annual growth rate (CAGR), from $221.38M to $501.9M.
- What does total assets mean?
- The sum of everything the company owns — current assets, property, investments, goodwill, intangibles, and all other assets.
Ask your AI about ImmunityBio, Inc.'s total assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude